DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIPOMERSEN SODIUM

« Back to Dashboard

Clinical Trials for Mipomersen Sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00362180	Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration	Completed	Ionis Pharmaceuticals, Inc.	Phase 2	2006-07-01	This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.
NCT00362180	Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration	Completed	Kastle Therapeutics, LLC	Phase 2	2006-07-01	This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis. In order to enroll subject groups with varying degrees of risk, the study has included multiple cohorts (Cohorts A-G). Additions and removal of cohorts has been accomplished with protocol amendments.
NCT00477594	Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia	Completed	Ionis Pharmaceuticals, Inc.	Phase 2	2007-05-01	The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
NCT00477594	Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia	Completed	Kastle Therapeutics, LLC	Phase 2	2007-05-01	The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.

Clinical Trial Conditions for Mipomersen Sodium

Condition Name

Condition Name for Mipomersen Sodium
Intervention	Trials
Hypercholesterolemia	7
Metabolic Disorder	5
Metabolic Diseases	5
Lipid Metabolism Disorders	5

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mipomersen Sodium
Intervention	Trials
Hypercholesterolemia	8
Lipid Metabolism Disorders	5
Dyslipidemias	5
Disease	5

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mipomersen Sodium

Trials by Country

Trials by Country for Mipomersen Sodium
Location	Trials
United States	73
Canada	12
United Kingdom	4
South Africa	3
Taiwan	2

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mipomersen Sodium
Location	Trials
Ohio	6
Missouri	4
Massachusetts	4
Florida	4
North Carolina	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mipomersen Sodium

Clinical Trial Phase

Clinical Trial Phase for Mipomersen Sodium
Clinical Trial Phase	Trials
Phase 3	5
Phase 2	3
Phase 1	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mipomersen Sodium
Clinical Trial Phase	Trials
Completed	9

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mipomersen Sodium

Sponsor Name

Sponsor Name for Mipomersen Sodium
Sponsor	Trials
Kastle Therapeutics, LLC	9
Ionis Pharmaceuticals, Inc.	9

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mipomersen Sodium
Sponsor	Trials
Industry	18

Export unavailable in trial.
Subscribe for complete access.